Clinical trials and regulatory approvals confirm that specific monoclonal antibody treatments, such as REGN-EB3 and mAb114, are effective in treating Ebola virus disease and significantly reducing mortality.
Evidence for · 4
Monoclonal Antibody Approved to Treat Ebola
2021 · cited by 4
Ansuvimab-zykl (Ebanga) is an approved human monoclonal antibody used to treat Zaire ebolavirus infection.
See more details
More for · 3
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.
2019 · cited by 0
A randomized controlled trial demonstrated that monoclonal antibody therapies such as MAb114 and REGN-EB3 are effective in reducing mortality from Ebola virus disease.
Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis.
2022 · cited by 0
A systematic review and network meta-analysis confirmed that treatments like REGN-EB3 and mAb114 significantly reduce mortality in patients with Ebola virus disease compared to standard care.
Viral hemorrhagic fevers - therapeutic trial advances and challenges.
2025 · cited by 0
Recent therapeutic advancements include monoclonal antibodies for Ebola virus disease that have demonstrated clinical efficacy.